Relmada Therapeutics, Inc.
DE ˙ DB ˙ US75955J4022
5,30 € ↓ -0,05 (-0,93%)
2026-06-04
DEL PRIS
SecurityDE:4E2 / Relmada Therapeutics, Inc.
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Ownership 1.70%
Citadel Advisors Llc ownership in 4E2 / Relmada Therapeutics, Inc.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (4E2) in the form of stock options. The firm currently holds call options representing 24,300 of underlying shares valued at $169,128 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2023-02-14 2023-02-14 13G/A 1.70 -61.36
2022-10-17 2022-10-17 13G 4.40

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:4E2 / Relmada Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F RELMADA THERAPEUTICS COM 75955J402 0 -28,063 -100.00 0 -100.00
2026-02-17 2025-12-31 13F RELMADA THERAPEUTICS COM 75955J402 28,063 28,063 136 0.0000
2025-02-14 2024-12-31 13F RELMADA THERAPEUTICS COM 75955J402 0 -52,846 -100.00 0 -100.00
2024-11-14 2024-09-30 13F RELMADA THERAPEUTICS COM 75955J402 52,846 -31,467 -37.32 171 -32.14 0.0000
2024-08-14 2024-06-30 13F RELMADA THERAPEUTICS COM 75955J402 84,313 13,769 19.52 253 -23.17 0.0001
2024-05-15 2024-03-31 13F RELMADA THERAPEUTICS COM 75955J402 70,544 -305,114 -81.22 328 -78.91 0.0001
2024-02-14 2023-12-31 13F RELMADA THERAPEUTICS COM 75955J402 375,658 -56,437 -13.06 1,555 19.98 0.0003
2023-11-14 2023-09-30 13F RELMADA THERAPEUTICS COM 75955J402 432,095 -155,699 -26.49 1,296 -10.31 0.0003
2023-08-14 2023-06-30 13F RELMADA THERAPEUTICS COM 75955J402 587,794 -82,239 -12.27 1,446 -4.56 0.0003
2023-05-15 2023-03-31 13F RELMADA THERAPEUTICS COM 75955J402 670,033 401,017 149.07 1,514 61.41 0.0003
2023-02-14 2022-12-31 13F RELMADA THERAPEUTICS COM 75955J402 269,016 -661,588 -71.09 939 -97.28 0.0002
2022-11-14 2022-09-30 13F RELMADA THERAPEUTICS COM 75955J402 930,604 -16,809 -1.77 34,451 91.48 0.0079
2022-08-15 2022-06-30 13F RELMADA THERAPEUTICS COM 75955J402 947,413 7,941 0.85 17,992 -29.04 0.0046
2022-05-16 2022-03-31 13F RELMADA THERAPEUTICS COM 75955J402 939,472 645,518 219.60 25,356 282.85 0.0052
2022-02-14 2021-12-31 13F RELMADA THERAPEUTICS COM 75955J402 293,954 -81,898 -21.79 6,623 -32.77 0.0014
2021-11-15 2021-09-30 13F RELMADA THERAPEUTICS Cmn 75955J402 375,852 12,869 3.55 9,851 -15.22 0.0020
2021-08-16 2021-06-30 13F RELMADA THERAPEUTICS COM 75955J402 362,983 352,522 3,369.87 11,619 3,057.34 0.0026
2021-05-21 2021-03-31 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 10,461 2,542 32.10 368 44.88 0.0001
2021-05-17 2021-03-31 13F RELMADA THERAPEUTICS COM 75955J402 10,461 2,542 368 0.0001
2021-02-16 2020-12-31 13F RELMADA THERAPEUTICS COM 75955J402 7,919 7,919 254 0.0001
2020-08-14 2020-06-30 13F RELMADA THERAPEUTICS Cmn 75955J402 0 -320,072 -100.00 0 -100.00
2020-05-15 2020-03-31 13F RELMADA THERAPEUTICS Cmn 75955J402 320,072 239,906 299.26 10,918 249.26 0.0049
2020-02-14 2019-12-31 13F RELMADA THERAPEUTICS Cmn 75955J402 80,166 80,166 3,126 0.0014
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F RELMADA THERAPEUTICS COM Call 24,300 -30.77 169 0.00 n/a n/a n/a
2026-02-17 2025-12-31 13F RELMADA THERAPEUTICS COM Call 35,100 91.80 170 369.44 n/a n/a n/a
2025-11-14 2025-09-30 13F RELMADA THERAPEUTICS COM Call 18,300 37 n/a n/a n/a
2025-05-15 2025-03-31 13F RELMADA THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-14 2024-12-31 13F RELMADA THERAPEUTICS COM Call 129,800 93.44 67 -69.12 n/a n/a n/a
2024-11-14 2024-09-30 13F RELMADA THERAPEUTICS COM Call 67,100 56.05 217 68.22 n/a n/a n/a
2024-08-14 2024-06-30 13F RELMADA THERAPEUTICS COM Call 43,000 8.31 129 -29.89 n/a n/a n/a
2024-05-15 2024-03-31 13F RELMADA THERAPEUTICS COM Call 39,700 48.69 185 67.27 n/a n/a n/a
2024-02-14 2023-12-31 13F RELMADA THERAPEUTICS COM Call 26,700 -21.47 111 7.84 n/a n/a n/a
2023-11-14 2023-09-30 13F RELMADA THERAPEUTICS COM Call 34,000 -64.51 102 -56.60 n/a n/a n/a
2023-08-14 2023-06-30 13F RELMADA THERAPEUTICS COM Call 95,800 -12.27 236 -4.47 n/a n/a n/a
2023-05-15 2023-03-31 13F RELMADA THERAPEUTICS COM Call 109,200 -54.93 247 -70.89 n/a n/a n/a
2023-02-14 2022-12-31 13F RELMADA THERAPEUTICS COM Call 242,300 -47.39 846 -95.04 n/a n/a n/a
2022-11-14 2022-09-30 13F RELMADA THERAPEUTICS COM Call 460,600 247.89 17,051 578.24 n/a n/a n/a
2022-08-15 2022-06-30 13F RELMADA THERAPEUTICS COM Call 132,400 147.48 2,514 74.10 n/a n/a n/a
2022-05-16 2022-03-31 13F RELMADA THERAPEUTICS COM Call 53,500 40.05 1,444 67.71 n/a n/a n/a
2022-02-14 2021-12-31 13F RELMADA THERAPEUTICS COM Call 38,200 -37.79 861 -46.49 n/a n/a n/a
2021-11-15 2021-09-30 13F RELMADA THERAPEUTICS Cmn Call 61,400 179.09 1,609 128.55 n/a n/a n/a
2021-08-16 2021-06-30 13F RELMADA THERAPEUTICS COM Call 22,000 -19.71 704 -27.05 n/a n/a n/a
2021-05-21 2021-03-31 13F/A RELMADA THERAPEUTICS COM Call 27,400 88.97 965 107.53 n/a n/a n/a
2021-05-17 2021-03-31 13F RELMADA THERAPEUTICS COM Call 27,400 965 n/a n/a n/a
2021-02-16 2020-12-31 13F RELMADA THERAPEUTICS COM Call 14,500 -26.40 465 -37.25 n/a n/a n/a
2020-11-16 2020-09-30 13F RELMADA THERAPEUTICS COM Call 19,700 741 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F RELMADA THERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-17 2025-12-31 13F RELMADA THERAPEUTICS COM Put 11,700 57 n/a n/a n/a
2025-05-15 2025-03-31 13F RELMADA THERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-14 2024-12-31 13F RELMADA THERAPEUTICS COM Put 46,500 -8.10 24 -85.28 n/a n/a n/a
2024-11-14 2024-09-30 13F RELMADA THERAPEUTICS COM Put 50,600 79.43 164 94.05 n/a n/a n/a
2024-08-14 2024-06-30 13F RELMADA THERAPEUTICS COM Put 28,200 -52.45 85 -69.45 n/a n/a n/a
2024-05-15 2024-03-31 13F RELMADA THERAPEUTICS COM Put 59,300 -24.27 276 -15.12 n/a n/a n/a
2024-02-14 2023-12-31 13F RELMADA THERAPEUTICS COM Put 78,300 47.46 324 103.77 n/a n/a n/a
2023-11-14 2023-09-30 13F RELMADA THERAPEUTICS COM Put 53,100 -30.95 159 -15.87 n/a n/a n/a
2023-08-14 2023-06-30 13F RELMADA THERAPEUTICS COM Put 76,900 135.89 189 158.90 n/a n/a n/a
2023-05-15 2023-03-31 13F RELMADA THERAPEUTICS COM Put 32,600 -65.86 74 -78.08 n/a n/a n/a
2023-02-14 2022-12-31 13F RELMADA THERAPEUTICS COM Put 95,500 -80.32 333 -98.15 n/a n/a n/a
2022-11-14 2022-09-30 13F RELMADA THERAPEUTICS COM Put 485,300 288.24 17,966 656.78 n/a n/a n/a
2022-08-15 2022-06-30 13F RELMADA THERAPEUTICS COM Put 125,000 210.95 2,374 118.80 n/a n/a n/a
2022-05-16 2022-03-31 13F RELMADA THERAPEUTICS COM Put 40,200 255.75 1,085 325.49 n/a n/a n/a
2022-02-14 2021-12-31 13F RELMADA THERAPEUTICS COM Put 11,300 -31.93 255 -41.38 n/a n/a n/a
2021-11-15 2021-09-30 13F RELMADA THERAPEUTICS Cmn Put 16,600 -9.29 435 -25.77 n/a n/a n/a
2021-08-16 2021-06-30 13F RELMADA THERAPEUTICS COM Put 18,300 38.64 586 26.02 n/a n/a n/a
2021-05-21 2021-03-31 13F/A RELMADA THERAPEUTICS COM Put 13,200 465 n/a n/a n/a
2021-05-17 2021-03-31 13F RELMADA THERAPEUTICS COM Put 13,200 465 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.